Close Menu

NEW YORK – Belgian drug developer Octimet Oncology said on Wednesday that it has exclusively licensed its lead clinical compound OMO-1 and another, unidentified preclinical-stage drug to Shanghai-based Allist Pharmaceuticals.

OMO-1, a selective MET kinase inhibitor, has demonstrated preliminary activity and safety as a single agent and in combination with an EGFR inhibitor in cancer patients with MET alterations in Europe. When MET is amplified in non-small cell lung cancers, it drives resistance to EGFR inhibitors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.